Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Shionogi licenses Akili's digital medicine candidates for ADHD, ASD

Executive Summary

Shionogi & Co. Ltd. secured exclusive development, marketing, and commercialization rights in Japan and Taiwan to Akili Interactive Labs Inc.’s digital therapeutic candidates AKLT01 (under review by the FDA for attention-deficit/hyperactivity disorder (ADHD)) and AKLT02 (late-stage development for cognitive dysfunction in pediatric autism spectrum disorder (ASD)). Both potential medicines are designed to be prescribed by a physician and delivered through immersive-action video games on a smartphone or tablet.
Deal Industry
  • Digital Health
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Monitoring Equipment & Devices
    • Rehabilitation Equipment and Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register